Elevance Health
ELV
Market cap $66.3B

294.43 USD

+1.95

0.67%

At close Aug 13, 4:00 PM EDT

After hours

294.30

-0.13

0.04%

1 day

0.67%

5 days

5.56%

1 month

-13.42%

3 months

-21.57%

6 months

-24.81%

Year to date

-19.52%

1 year

-44.62%

5 years

4.29%

10 years

96.69%

About: Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of June 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.

Employees: 104,200

Healthcare Healthcare Plans

0

Funds holding %

of 7,338 funds

0

Analysts bullish %

of 10 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

57% more first-time investments, than exits

New positions opened: 215 | Existing positions closed: 137

36% more call options, than puts

Call options by funds: $801M | Put options by funds: $588M

23% more repeat investments, than reductions

Existing positions increased: 645 | Existing positions reduced: 526

14% more capital invested

Capital invested by funds: $76.2B [Q4 2024] → $87B (+$10.8B) [Q1 2025]

13% more funds holding in top 10

Funds holding in top 10: 38 [Q4 2024] → 43 (+5) [Q1 2025]

3% more funds holding

Funds holding: 1,576 [Q4 2024] → 1,626 (+50) [Q1 2025]

1.17% less ownership

Funds ownership: 89.26% [Q4 2024] → 88.09% (-1.17%) [Q1 2025]

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$297

1%

upside

Avg. target

$375

27%

upside

High target

$478

62%

upside

10 analyst ratings

8 positive

80%

2 neutral

20%

0 negative

0%

Baird Michael Ha	1%upside $297	Neutral Maintained	25 Jul 2025
JP Morgan Lisa Gill	30%upside $384	Overweight Maintained	22 Jul 2025
Barclays Andrew Mok	11%upside $327	Overweight Maintained	22 Jul 2025
UBS A.J. Rice	48%upside $435	Buy Maintained	18 Jul 2025
Guggenheim Jason Cassorla	22%upside $360	Buy Maintained	18 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 22 articles about ELV published over the past 30 days

Zacks Investment Research

When 90% Isn't an A+: Elevance's Cost Crunch and Carelon's Cushion

ELV trims 2025 outlook as medical costs climb, but commercial growth and Carelon's momentum aim to steady performance.

When 90% Isn't an A+: Elevance's Cost Crunch and Carelon's Cushion

Zacks Investment Research

When a Healthcare Giant Gets Sick: Elevance Health's 20% YTD Decline

ELV's 20% YTD slump reflects shrinking memberships, rising costs and deepening analyst pessimism despite long-term growth levers.

When a Healthcare Giant Gets Sick: Elevance Health's 20% YTD Decline

24/7 Wall Street

3 Stocks That Could Double Before 2027

These stocks have high upside potential through 2027. They're sitting at solid discounts and have good fundamentals.

3 Stocks That Could Double Before 2027

3 SWANs On Sale

Our focus for today includes BMY, REXR, and ELV. The trio offers a safe 4.2% dividend yield, an A- credit rating average, and a 27% weighted discount to fair value. Bristol-Myers Squibb possesses a lineup of blockbuster drugs and a solid pipeline of drugs, an A S&P credit rating, and offers a safe and sizable yield. Rexford Industrial Realty owns high-value, mission-critical real estate, pays a well-covered dividend, and has a BBB+ S&P credit rating.

3 SWANs On Sale

Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts

Insmed, Intuitive Surgical, and IDEXX Laboratories were top contributors, driven by strong drug pipelines, innovation, and robust financial results. We exited UnitedHealth Group due to earnings misses, guidance cuts, and Medicare Advantage mispricing, despite its long-term potential to restore profitability. Thermo Fisher and argenx detracted from performance amid macro headwinds and lower-than-expected sales, but we retain conviction in their long-term prospects.

Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts

Elevance Health Board Welcomes Steve Collis as New Director, Reflecting Ongoing Commitment to Governance Excellence

INDIANAPOLIS--(BUSINESS WIRE)--The board of directors of Elevance Health (NYSE: ELV) announced today that Steve Collis, a highly regarded global healthcare executive, will be joining the company's board, effective August 1. He will also serve on the board's Audit and Finance Committees, further enhancing the board's industry expertise and financial oversight capabilities. His addition is part of the board's ongoing commitment and structured approach to refresh its membership in support of the c.

Elevance Health Board Welcomes Steve Collis as New Director, Reflecting Ongoing Commitment to Governance Excellence

Centene, Cigna, Others Drop As Molina's Results Rattle Sector

Molina Healthcare Inc. MOH missed Wall Street expectations in its second-quarter earnings report Wednesday, triggering a selloff across the healthcare insurance sector.

Centene, Cigna, Others Drop As Molina's Results Rattle Sector

Elevance Health: CEO Buys As CareBridge Drives Strong Growth

On July 18, the CEO bought $2.4MM worth, after the sell-off following the last earnings call. Carelon Services is growing fast, supported by the December acquisition of CareBridge. The aging population, the rising interest in well-being, and the potential expansion in Florida and Texas are a ray of light in the current gloomy context of the company.

Elevance Health: CEO Buys As CareBridge Drives Strong Growth

Study Finds Digital Asthma Program Significantly Improves Symptom Control in Adults

INDIANAPOLIS--(BUSINESS WIRE)-- #DigitalHealth--Study by Elevance Health, UCI, in collaboration with Apple, highlights potential of digital health tools to reduce asthma burden in U.S. populations.

Study Finds Digital Asthma Program Significantly Improves Symptom Control in Adults

Zacks Investment Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

See News Rankings

Charts implemented using Lightweight Charts™